Celleo originated at the intersection of great biology and great engineering. Sparks fly at the intersection.

Our mission is to enable cell therapies to deliver population-level health outcomes, realizing the extraordinary potential of humanity’s most powerful therapeutic modality – our cells, augmented.

We contribute intelligent production systems for the manufacture of cell therapies.

Our founders each bring 20 years of deep industry experience in the development and production of cell therapies. Celleo develops GMP production systems in collaboration with leading commercial biotherapeutics players, CDMOs, developers of novel therapeutics at pre-clinical to clinical stage, and major university medical centres.

Our production systems seek to accommodate, not dictate, the diversity of processes, modalities and business models characteristic of our vibrant industry.

Steve Jobs predicted “…the biggest innovations of the 21st century will be at the intersection of biology and technology.” Today’s cell therapy industry is approaching a tipping point – from a limited set of therapeutics changing the lives of a fortunate few, to a broadly available toolkit for physicians providing a new standard of personalized care. We’re here to hasten that transition.

Millions of patients in need deserve it.

Thousands of cell therapy professionals deserve it too.

Celleo’s team are hand-picked industry veterans, averaging over 15 years’ cell therapy experience.

We’re skilled technical specialists, across a broad set of bioscience, manufacturing, engineering, and design disciplines.

We’re consummate professionals, managing global quality and regulatory environments, diverse and demanding customer requirements, robust supply-chains, and disciplined service and support.

We’re curious and driven, solving industry bottlenecks with innovative technology platforms that expand our customers’ potential.

We’re focused and engaged, disrupting cell therapy manufacturing to bring better therapies to more patients.

We are Celleo.

Celleo’s founders have each pushed the forefront of automated cell therapy manufacturing for over 20 years.

CEO David Kneen and CTO Mark Rob have together managed over 50 automation programs developing scaled GMP commercial manufacturing across cell, gene and tissue therapies, other advanced biologicals, and ancillary materials.

Our development experience spans laboratory devices through multi-skid automated production lines, covering installation across North America, Europe/UK, and Asia-Pacific, and working with large biopharma, CDMOs, novel pre-clinical therapeutics and specialised device developers.